1501pcomparison of the Efficacy of Filgrastim (neupogen®) and Biosimilar Filgrastim (leucostim®) in Patients with Chemotherapy-induced Neutropenia: a Nationwide Observational Study.
نویسندگان
چکیده
A. Sevinc1, M. Ozkan2, A. Ozet3, F. Dane4, B. Oksuzoglu5, A. Isikdogan6, F. Ozdemir7, D. Uncu8, M. Gumus9, T. Evrensel10, A. Yaren11, O. Kara12, S.B. TekIṅ13 Medical Oncology Department, Gaziantep University Onkoloji Hastanesi, Gaziantep, TURKEY Medical Oncology, Erciyes University Medical Faculty M. Kemal Dedeman, Oncology Hospital, Kayseri, TURKEY Medical Oncology, Gazi University Faculty of Medicine, Ankara, TURKEY Medical Oncology Department, Marmara University Hospital, Istanbul, TURKEY Department of Medical Oncology, Ankara Dr. A.Y.Oncology Research and Education Hospital, Ankara, TURKEY Medical Oncology, Dicle University, Diyarbakir, TURKEY Medical Oncology Dept., Karadeniz Technical UniversityMedical Faculty, Trabzon, TURKEY Medical Oncology, Ankara Numune Education and Research Hospital, Ankara, TURKEY Dept. Medical Oncology, Bezmialem Vakif University Hospital, Istanbul, TURKEY Medıcal Oncology, Uludag University Medıcıne Faculty, Bursa, TURKEY Medical Oncology, Pamukkale University School of Medicine, Denizli, TURKEY Medical Oncology, Cukurova University Medical Faculty, Adana, TURKEY Medical Oncology, Ataturk University, Erzurum, TURKEY
منابع مشابه
Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia
Background We studied the comparative effectiveness of biosimilar filgrastim vs original filgrastim in patients with chemotherapy-induced neutropenia. Patients and methods This multicenter, observational study was conducted at 14 centers. The study included 337 patients experiencing neutropenia under chemotherapy. Patients were given either filgrastim 30 MIU or 48 MIU (Neupogen®) or biosimila...
متن کاملPrevention and treatment of chemotherapy-induced neutropenia with the biosimilar filgrastim: a non-interventional observational study of clinical practice patterns.
BACKGROUND Biosimilars are similar but non-identical versions of existing biological drugs. The HEXAFIL study was an observational study that assessed the clinical usage, safety and efficacy of the biosimilar filgrastim in routine clinical practice in Germany. PATIENTS AND METHODS A total of 1,337 cancer patients received the biosimilar filgrastim for primary prophylaxis (PP), secondary proph...
متن کاملCompatibility of Biosimilar Filgrastim with Cytotoxic Chemotherapy during the Treatment of Malignant Diseases (VENICE): A Prospective, Multicenter, Non-Interventional, Longitudinal Study
INTRODUCTION Febrile neutropenia (FN) is a serious and frequent complication of cytotoxic chemotherapy. Biosimilar filgrastim (Nivestim™, Hospira Inc, A Pfizer Company, Lake Forest, IL, USA) is a granulocyte-colony stimulating factor licensed for the treatment of neutropenia and FN induced by myelosuppressive chemotherapy. The primary goal of this VENICE study (ClinicalTrials.gov identifier, NC...
متن کاملA phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients
OBJECTIVES: To compare the efficacy and safety of two filgrastim formulations for controlling chemotherapy-induced neutropenia and to evaluate the non-inferiority of the test drug relative to the originator. METHODS: This phase III non-inferiority study had a randomized, multicenter, and open-label design. The patients were randomized at a ratio of 1:1 with a follow-up period of 6 weeks for e...
متن کاملRole of lipegfilgrastim in the management of chemotherapy-induced neutropenia
Chemotherapy, irradiation, and other agents are widely used to target the process of cell division in neoplastic cells. However, while these therapies are effective against most cancers, the high proliferative rate of the cells of the hematopoietic system that produce billions of blood cells needed daily throughout life is extremely sensitive to these agents, resulting in loss of blood cell pop...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Annals of oncology : official journal of the European Society for Medical Oncology
دوره 25 suppl_4 شماره
صفحات -
تاریخ انتشار 2014